Where Science meets Business

The Tech Park Basel is the premier address for early-stage tech start-ups in Basel. It offers a collaboration-friendly, yet business-driven environment and is part of the rapidly growing Stücki Park in the dynamic northern part of Basel. The Tech Park Basel provides office space and fully equipped laboratories at highly favorable terms, and offers shared facilities and a variety of other services to tech start-ups.

About us

Workspace designed for people to innovate, connect and thrive.

We run the infrastructure so you can run your organisation.
 
LEARN MORE

News

Alentis Therapeutics Raises USD 67 Million in Series B Financing

by

15.06.2021
Basel, Switzerland and Strasbourg, France, 15 June 2021 — Alentis Therapeutics, the Swiss biotech developing breakthrough treatments for fibrotic diseases, today announced that it has raised USD67 (CHF60) million in a Series B financing round.

We are hiring an additional female Board Member

by

11.05.2021
Der Tech Park Basel wurde über die letzten zehn Jahre im Stücki Park im Norden von Basel auf- und ausgebaut. Heute bietet er auf rund 6'700 m2 für über 30 innovative, technologieorientierte Start-ups ein inspirierendes Umfeld und verleiht der Wirtschaft im Kanton Basel- Stadt wichtige Impulse.

POLYNEURON AWARDED GRANT OF CHF 1.2M

by

05.05.2021
Polyneuron Pharmaceuticals AG, a clinical-stage developer of a new class of antigen-specific polymers for the treatment of patients with serious autoimmune diseases, today announced that the company and collaborators at the University of Basel have received a grant from the Swiss Innovation Agency Innosuisse to support a project valued at CHF 1.2 million.

Start-up Insights

Monte Rosa: From idea to IPO in the Tech Park Basel

John Castle Chief Data Science Officer of Monte Rosa Therapeutics

to the full story

Artidis: Cancer diagnosis in less than 3 hours

Marija Plodinec CEO of Artidis

to the full story

Cellestia Biotech: A novel method from Basel to fight cancer

Michael Bauer CEO Cellestia Biotech

to the full story

NBE Therapeutics: Cancer drugs with a twist for fewer side effects

Ulf Grawunder, Founder of NBE Therapeutics

to the full story

Edelweiss Connect: Product safety with minimal animal testing

Barry Hardy CEO of Edelweiss Connect

to the full story

Tenants